These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 26517521)

  • 21. Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line.
    Zou H; Cao X; Xiao Q; Sheng X; Ren K; Quan M; Song Z; Li D; Zheng Y; Zeng W; Cao J; Peng Y
    Oncol Rep; 2016 Sep; 36(3):1731-8. PubMed ID: 27461522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4.
    Tian L; Shen D; Li X; Shan X; Wang X; Yan Q; Liu J
    Oncotarget; 2016 Jan; 7(2):1619-32. PubMed ID: 26636541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bornyl
    Yang TY; Wu ML; Chang CI; Liu CI; Cheng TC; Wu YJ
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Luteolin inhibits proliferation and induces apoptosis of human melanoma cells in vivo and in vitro by suppressing MMP-2 and MMP-9 through the PI3K/AKT pathway.
    Yao X; Jiang W; Yu D; Yan Z
    Food Funct; 2019 Feb; 10(2):703-712. PubMed ID: 30663726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
    Lasithiotakis KG; Sinnberg TW; Schittek B; Flaherty KT; Kulms D; Maczey E; Garbe C; Meier FE
    J Invest Dermatol; 2008 Aug; 128(8):2013-23. PubMed ID: 18323781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition.
    Leight JL; Tokuda EY; Jones CE; Lin AJ; Anseth KS
    Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5366-71. PubMed ID: 25870264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway.
    Li CY; Wang Q; Wang X; Li G; Shen S; Wei X
    Eur J Pharmacol; 2019 Sep; 858():172463. PubMed ID: 31211986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
    Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
    Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways.
    Li CY; Wang Q; Wang XM; Li GX; Shen S; Wei XL
    Eur J Pharmacol; 2019 Dec; 864():172719. PubMed ID: 31586634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner.
    Park GB; Ko HS; Kim D
    Mol Med Rep; 2017 Aug; 16(2):1826-1836. PubMed ID: 28627617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.
    Ziegler E; Hansen MT; Haase M; Emons G; Gründker C
    Breast Cancer Res Treat; 2014 Nov; 148(2):269-77. PubMed ID: 25292421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MMP-2 and MMP-9 mediate cigarette smoke extract-induced epithelial-mesenchymal transition in airway epithelial cells via EGFR/Akt/GSK3β/β-catenin pathway: Amelioration by fisetin.
    Agraval H; Yadav UCS
    Chem Biol Interact; 2019 Dec; 314():108846. PubMed ID: 31606474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
    Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
    J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fisetin inhibits migration, invasion and epithelial-mesenchymal transition of LMP1-positive nasopharyngeal carcinoma cells.
    Li R; Zhao Y; Chen J; Shao S; Zhang X
    Mol Med Rep; 2014 Feb; 9(2):413-8. PubMed ID: 24297333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
    López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
    Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts.
    Zhou Q; Guo X; Choksi R
    J Pharmacol Exp Ther; 2017 Dec; 363(3):428-443. PubMed ID: 29021381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.